Moderna (MRNA) priced a $2.6 billion offering of convertible senior notes due 2032, up from the previously announced $2 billion, the company said Friday.
Initial purchasers were granted an option to buy up to an additional $400 million of notes, the company said.
The company expects to use the net proceeds to pay the cost of certain capped call transactions and for general corporate purposes, including potential investments in its oncology business and debt repayment, it added.
The company expects the sale to initial purchasers to close Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments